Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Depreciation and Depletion (2016)

Lineage Cell Therapeutics' Depreciation and Depletion history spans 7 years, with the latest figure at $248000.0 for Q3 2016.

  • For Q3 2016, Depreciation and Depletion fell 6.06% year-over-year to $248000.0; the TTM value through Sep 2016 reached $1.3 million, up 25.65%, while the annual FY2015 figure was $1.1 million, 2.57% up from the prior year.
  • Depreciation and Depletion reached $248000.0 in Q3 2016 per LCTX's latest filing, down from $319000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $429000.0 in Q1 2016 to a low of $88692.0 in Q1 2012.
  • Average Depreciation and Depletion over 5 years is $217650.4, with a median of $249000.0 recorded in 2015.
  • Peak YoY movement for Depreciation and Depletion: fell 24.75% in 2012, then surged 134.71% in 2014.
  • A 5-year view of Depreciation and Depletion shows it stood at $102820.0 in 2012, then soared by 130.86% to $237370.0 in 2013, then rose by 8.27% to $257000.0 in 2014, then increased by 17.51% to $302000.0 in 2015, then dropped by 17.88% to $248000.0 in 2016.
  • Per Business Quant, the three most recent readings for LCTX's Depreciation and Depletion are $248000.0 (Q3 2016), $319000.0 (Q2 2016), and $429000.0 (Q1 2016).